ASCO 2025 overall survival data bolster IMNN-001’s potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of ...

REGISTER HERE It is recommended that investors pre-register an LAWRENCEVILLE, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development ...

Dr Lindborg shares her journey to her present role, the true potential shown in this new data for addressing unmet needs in ...

IMUNON announces promising Phase 1 results for IMNN-101, a DNA plasmid vaccine demonstrating enhanced durability and potential advantages over mRNA vaccines. Phase 1 clinical trial results of IMNN ...

US-based biotechnology company Imunon has reported positive results from its Phase II OVATION 2 trial of IMNN-001 for ovarian ...

LAWRENCEVILLE, N.J., June 17, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company focused on developing non-viral DNA-mediated immunotherapies and evaluating an adaptati ...

Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed Gynecologic Oncology, suggest very meaningful survival effect of IMNN-001 in women HRP and HRD positive, ...

About IMNN-001 Immunotherapy Designed using IMUNON's proprietary TheraPlas ® platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that ...

Imunon formally requested to retract its Form S-1 registration with the SEC after initially registering the document on April 4. The biotech firm's shares rose 4.1% to $0.42 on Thursday and surged ...

Imunon (IMNN) announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 7,222,223 shares of its common stock or pre-funded warrants in lieu therof and short ...

IMUNON, Inc. raises $3.25 million through the sale of shares and warrants, potentially totaling $9.75 million with full warrant exercise. IMUNON, Inc. has completed a private placement raising ...